JPM 2022: Vertex's Trikafta holds the line as company lays groundwork for gene editing launch

Vertex Pharmaceuticals is well known for its slew of cystic fibrosis medications, and newcomer Trikafta is pulling its weight. Over the course of 2021, the med clinched reimbursement in 16 countries and launched for kids ages 6 to 11 in the U.S.

Together, those advances teed up “thousands” of new patients starting on the nascent blockbuster. Meanwhile, Vertex sees potential for “significant” cystic fibrosis growth “well into the middle of the decade,” CEO Reshma Kewalramani said during the company’s presentation at the 2022 virtual J.P. Morgan healthcare conference.